Study to Investigate Dose Proportionality of the Fixed Dose Combination of COREG CR and Lisinopril.
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
COREG CR and lisinopril (FDC)
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension focused on measuring COREG CR,, lisinopril,, hypertension,, dose proportionality,, fixed dose combination (FDC)
Eligibility Criteria
Inclusion criteria:
- Healthy volunteer Adult males and females of non-child bearing potential who are between 18 to 55 years of age, inclusively
- Body weight > 60 kg (132 lbs) and body mass index (BMI) between 19 and 33
Exclusion criteria:
- Any clinically relevant abnormality identified on the screening history, physical or laboratory examination, or any other medical condition or circumstance making the volunteer unsuitable for participation in the study.
- Subjects who metabolize carvedilol poorly based on CYP2D6 genotyping as determined at screening.
- Treatment with any prescription or non-prescription drugs (including vitamins, herbal and dietary supplements, as well as grapefruit-containing products) within 7 days or 5 half-lives (whichever is longer) prior to first dose of study medication and until the end of the study. Treatment with any CYP2D6 inhibitors such as but not limited to quinidine, fluoxetine, paroxetine, duloxetine, and terbinofine at least 14 days or 5 half-lives (whichever is longer) prior to Day 1 of Session 1 and until the end of the study.
- Treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding Day 1 of Session 1
- Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- History of regular alcohol consumption exceeding 7 drinks/week for women or 14 drinks/week for men (1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard liquor) within 6 months of screening.
- Positive urine drug screen (UDS) including alcohol at screening. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiazepines.
- Urine Na/creatinine ratio < 0.1 meq/mg.
- Positive for Hepatitis B surface antigen, or HIV.
- Women of child-bearing potential.
- Resting heart rate of >/ 50 beats per minute (bpm) at screening.
- Abnormalities on 12-lead ECG during screening
- Documented history of low blood pressure (average SBP ≤ 110 mm Hg and/or DBP ≤ 50 mm Hg) or blood pressure below these values at time of screening.
- Orthostatic hypotension diagnosed at screening (orthostatic hypotension will be defined as a reduction in systolic blood pressure of 20 mmHg or more and/or a reduction in diastolic blood pressure of 10 mmHg or more for standing vs. supine measurements.
- Donation of blood in excess of 500 mL within a 56 day period including the estimated 550 mL of blood to be drawn during this study.
- History of asthma, COPD and/or hypersensitivity to β-adrenergic blocking agents.
- History of sensitivity to heparin, heparin-induced thrombocytopenia, or sensitivity to any of the study medications or components thereof.
- History of anaphylaxis or anaphalactoid reactions or severe allergic responses to drugs.
- History of angioedema.
- History of sensitivity to carvedilol, lisinopril, alpha-blockers, beta-blockers or ACE inhibitors
- Unwillingness or inability to follow the procedures outlined in the protocol or inability to provide written informed consent.
Sites / Locations
- GSK Investigational Site
Outcomes
Primary Outcome Measures
Assessment of dose proportionality by comparison of PK parameters across dosing range Blood sampling over up to a 120 hour period post dose in all dosing sessions
Secondary Outcome Measures
Characterization of PK, safety and tolerability Safety and tolerability will be assessed by clinical data from spontaneous Adverse Event reporting, nurse/physician observations, vital sign assessment, ECGs, and clinical laboratory tests
The pharmacokinetic parameters to be evaluated are the Tmax and t1/2 of carvedilol [R(+) and S(-)enantiomers] and Tmax and t1/2 of lisinopril
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00549510
Brief Title
Study to Investigate Dose Proportionality of the Fixed Dose Combination of COREG CR and Lisinopril.
Official Title
A Non-randomized, Open-label, Single-dose, Crossover Study to Evaluate the Dose Proportionality of the Final Fixed Dose Combination Formulation of COREG CR™ and Lisinopril.
Study Type
Interventional
2. Study Status
Record Verification Date
October 2010
Overall Recruitment Status
Completed
Study Start Date
October 2007 (undefined)
Primary Completion Date
December 2007 (Actual)
Study Completion Date
December 2007 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
GlaxoSmithKline
4. Oversight
5. Study Description
Brief Summary
This will be an open-label, single-dose, non-randomized, five-period crossover study in healthy volunteers. The duration of the study will last up to eleven weeks from screening to follow-up. PK samples will be taken.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
COREG CR,, lisinopril,, hypertension,, dose proportionality,, fixed dose combination (FDC)
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
29 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
COREG CR and lisinopril (FDC)
Primary Outcome Measure Information:
Title
Assessment of dose proportionality by comparison of PK parameters across dosing range Blood sampling over up to a 120 hour period post dose in all dosing sessions
Secondary Outcome Measure Information:
Title
Characterization of PK, safety and tolerability Safety and tolerability will be assessed by clinical data from spontaneous Adverse Event reporting, nurse/physician observations, vital sign assessment, ECGs, and clinical laboratory tests
Title
The pharmacokinetic parameters to be evaluated are the Tmax and t1/2 of carvedilol [R(+) and S(-)enantiomers] and Tmax and t1/2 of lisinopril
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion criteria:
Healthy volunteer Adult males and females of non-child bearing potential who are between 18 to 55 years of age, inclusively
Body weight > 60 kg (132 lbs) and body mass index (BMI) between 19 and 33
Exclusion criteria:
Any clinically relevant abnormality identified on the screening history, physical or laboratory examination, or any other medical condition or circumstance making the volunteer unsuitable for participation in the study.
Subjects who metabolize carvedilol poorly based on CYP2D6 genotyping as determined at screening.
Treatment with any prescription or non-prescription drugs (including vitamins, herbal and dietary supplements, as well as grapefruit-containing products) within 7 days or 5 half-lives (whichever is longer) prior to first dose of study medication and until the end of the study. Treatment with any CYP2D6 inhibitors such as but not limited to quinidine, fluoxetine, paroxetine, duloxetine, and terbinofine at least 14 days or 5 half-lives (whichever is longer) prior to Day 1 of Session 1 and until the end of the study.
Treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding Day 1 of Session 1
Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
History of regular alcohol consumption exceeding 7 drinks/week for women or 14 drinks/week for men (1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard liquor) within 6 months of screening.
Positive urine drug screen (UDS) including alcohol at screening. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiazepines.
Urine Na/creatinine ratio < 0.1 meq/mg.
Positive for Hepatitis B surface antigen, or HIV.
Women of child-bearing potential.
Resting heart rate of >/ 50 beats per minute (bpm) at screening.
Abnormalities on 12-lead ECG during screening
Documented history of low blood pressure (average SBP ≤ 110 mm Hg and/or DBP ≤ 50 mm Hg) or blood pressure below these values at time of screening.
Orthostatic hypotension diagnosed at screening (orthostatic hypotension will be defined as a reduction in systolic blood pressure of 20 mmHg or more and/or a reduction in diastolic blood pressure of 10 mmHg or more for standing vs. supine measurements.
Donation of blood in excess of 500 mL within a 56 day period including the estimated 550 mL of blood to be drawn during this study.
History of asthma, COPD and/or hypersensitivity to β-adrenergic blocking agents.
History of sensitivity to heparin, heparin-induced thrombocytopenia, or sensitivity to any of the study medications or components thereof.
History of anaphylaxis or anaphalactoid reactions or severe allergic responses to drugs.
History of angioedema.
History of sensitivity to carvedilol, lisinopril, alpha-blockers, beta-blockers or ACE inhibitors
Unwillingness or inability to follow the procedures outlined in the protocol or inability to provide written informed consent.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
GSK Clinical Trials, MD
Organizational Affiliation
GlaxoSmithKline
Official's Role
Study Director
Facility Information:
Facility Name
GSK Investigational Site
City
Austin
State/Province
Texas
ZIP/Postal Code
78744
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Study to Investigate Dose Proportionality of the Fixed Dose Combination of COREG CR and Lisinopril.
We'll reach out to this number within 24 hrs